Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Carotenoid Status and Psychological Impact of Presymptomatic Macular Degeneration Genetic Risk Assessment: The MAGENTA Randomized Trial.

Ophthalmology science·2026

Same author

Retinal Carotenoid Supplementation Increases HDL Cholesterol in Humans and Mice.

Life (Basel, Switzerland)·2026

Same author

Is occlusive retinal vascular disease linked to hereditary spherocytosis postsplenectomy? A case series.

Journal of medical case reports·2025

Same author

Mechanism of Lutein to <i>meso</i>-Zeaxanthin Isomerization by RPE65 Catalysis.

bioRxiv : the preprint server for biology·2025

Same author

Delayed-onset <i>Moraxella nonliquefaciens</i> endophthalmitis following intravitreal injection.

American journal of ophthalmology case reports·2025

Same author

Natural History of Microperimetry and Optical Coherence Tomography in USH2A-Retinopathy: A Structure-Function Association Study.

American journal of ophthalmology·2025

Search research articles

Related Experiment Video

Updated: Mar 25, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

EZOGABINE (POTIGA) MACULOPATHY.

Brian E Zaugg¹, James E Bell, Kim Y Taylor

¹Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah.

Retinal Cases & Brief Reports

|February 25, 2016

Summary

Ezogabine, an epilepsy medication, can cause retinal toxicity presenting as macular pigment changes. These changes may be partially reversible after discontinuing the drug.

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Related Experiment Videos

Last Updated: Mar 25, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Area of Science:

Ophthalmology
Neuroscience
Pharmacology

Background:

Ezogabine (Potiga) is a newer antiepileptic medication.
Ocular toxicity is a known concern requiring monitoring.
Routine screening is recommended by the FDA.

Observation:

A patient developed new retinal pigment abnormalities in both maculas 9 months after starting ezogabine.
Multimodal imaging was used to characterize these changes.
The observed abnormalities were partially reversible upon drug cessation.

Findings:

Ezogabine-induced retinal toxicity manifests as pigmentary changes in the macula.
This case provides novel multimodal imaging characteristics of ezogabine maculopathy.
The findings highlight the importance of regular ophthalmic screening.

Implications:

Ophthalmologists can use these imaging characteristics to identify ezogabine toxicity.
Early detection through screening can guide management and potentially reverse visual changes.
This case contributes to understanding the ocular side effects of newer antiepileptic drugs.